Alzheimer’s disease biomarkers for determining prognosis in reverting mild cognitive impairment


  • In individuals with mild cognitive impairment (MCI) that revert to normal cognition (NC) i.e. MCI reverters, the presence of aberrant biomarkers for AD (Alzheimer’s disease) pathology is associated with subsequent clinical decline.

Why this matters

  • Biomarkers associated with AD pathology may assist in the prognosis of reverting MCI and early identification of individuals at high risk of dementia can help in increasing prognosis confidence as well as healthcare planning.